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Background: Interstitial lung disease is a major cause of morbidity and mortality in systemic sclerosis (SSc), with
insufficiently effective treatment options. Progression of pulmonary fibrosis involves expanding populations of
fibroblasts, and the accumulation of extracellular matrix proteins. Characterisation of SSc lung fibroblast gene
expression profiles underlying the fibrotic cell phenotype could enable a better understanding of the processes
leading to the progressive build-up of scar tissue in the lungs. In this study we evaluate the transcriptomes of
fibroblasts isolated from SSc lung biopsies at the time of diagnosis, compared with those from control lungs.
Methods: We used Affymetrix oligonucleotide microarrays to compare the gene expression profile of pulmonary
fibroblasts cultured from 8 patients with pulmonary fibrosis associated with SSc (SSc-ILD), with those from control
lung tissue peripheral to resected cancer (n=10). Fibroblast cultures from 3 patients with idiopathic pulmonary
fibrosis (IPF) were included as a further comparison. Genes differentially expressed were identified using two
separate analysis programs following a set of pre-determined criteria: only genes significant in both analyses were
considered. Microarray expression data was verified by qRT-PCR and/or western blot analysis.
Results: A total of 843 genes were identified as differentially expressed in pulmonary fibroblasts from SSc-ILD and/
or IPF compared to control lung, with a large overlap in the expression profiles of both diseases. We observed
increased expression of a TGF-β response signature including fibrosis associated genes and myofibroblast markers,
with marked heterogeneity across samples. Strongly suppressed expression of interferon stimulated genes,
including antiviral, chemokine, and MHC class 1 genes, was uniformly observed in fibrotic fibroblasts. This
expression profile includes key regulators and mediators of the interferon response, such as STAT1, and CXCL10, and
was also independent of disease group.
Conclusions: This study identified a strongly suppressed interferon-stimulated gene program in fibroblasts from
fibrotic lung. The data suggests that the repressed expression of interferon-stimulated genes may underpin critical
aspects of the profibrotic fibroblast phenotype, identifying an area in pulmonary fibrosis that requires further
investigation.
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Pulmonary fibrosis, characterised by the destruction of
lung architecture leading to organ failure, is, together
with pulmonary hypertension (PH), the leading cause of
death in patients with systemic sclerosis (SSc) [1]. Intersti-
tial lung disease is more common in SSc (SSc-ILD) than
in any other connective tissue disease, occurring in > 70%
of patients [2], and is most frequently associated with a
pattern of non-specific interstitial pneumonia (NSIP) [3].
Despite intense research efforts, the underlying mecha-
nisms of SSc-ILD remain largely unknown [4], and there
are currently limited therapeutic options for this serious
complication [2].
While a large number of hypothesis-driven studies
have identified potential profibrotic mediators [4,5], transla-
tion of these into therapeutic targets has so far been largely
disappointing [6]. The search for more effective targets in
lung fibrosis is now being addressed using hypothesis
generating microarray-based strategies [7,8]. The majority
of these studies have investigated gene expression in whole
lung tissue samples, mostly in the idiopathic setting [5].
Matrix metalloproteinase (MMP) 7 [9], osteopontin [10],
Twist1 [11], and MMP19 [12], are among suggested media-
tors identified using this strategy in idiopathic pulmonary
fibrosis (IPF), a disease characterised by a histological pat-
tern of usual interstitial pneumonia (UIP) [13,14]. In SSc,
most microarray studies have been performed on skin biop-
sies and dermal fibroblasts [7]. However, a recent study
compared whole lung tissue and fibroblasts isolated, at the
time of transplant, from SSc-ILD lungs with a histological
pattern of UIP, with those from IPF and idiopathic PH. The
investigators reported gene profiles of SSc-ILD/UIP, with ei-
ther predominant fibrosis or PH, overlapping with profiles
of IPF and idiopathic PH, respectively [15].
While the initiating factors for fibrosis development
may vary between diseases, the progressive accumulation
of scar tissue in the lung is characterised by common
themes, including expanding populations of activated fi-
broblasts, and excessive accumulation of extracellular
matrix (ECM) proteins [5]. An important strategy to iden-
tify potential therapeutic targets, therefore, is to define fi-
brotic fibroblast phenotypes so as to delineate underlying
key mechanisms for fibrosis progression.
Here we report analysis of the transcriptome of fibro-
blasts isolated from surgical lung biopsies at the time of
diagnosis, from patients with well defined SSc-ILD and
the histopathological pattern of NSIP. Although the main
aim of this study was to compare SSc-ILD/NSIP fibroblast
gene expression profiles with those of control lung fibro-
blasts, we also included a small number of IPF-derived
fibroblast lines, as a separate fibrotic group. Our study
confirms, with a robust signature in both diseases, the ab-
errant expression of previously reported myofibroblast
markers and fibrosis mediators, and identifies a number ofnovel, co-expressed putative disease targets. We also ob-
served the suppression of a large gene program, the inter-
feron stimulated genes (ISGs), reported here for the first
time. From the known function of some of these genes
[16], it is possible to hypothesise that this suppressed pro-
gram underlies key fibrotic fibroblast properties, such as
hyper-proliferation, and apoptosis resistance. This study
therefore identifies a potential new area for investigation
and possible intervention in pulmonary fibrosis.
Methods
Patients and primary lung fibroblasts
Primary adult pulmonary fibroblasts were cultured from
control tissue samples of unaffected lung from patients
undergoing cancer-resection surgery (n=10), and from
surgical lung biopsy samples of 11 patients with pul-
monary fibrosis (SSc-ILD n=8 and IPF n=3). Independ-
ent reviews of the clinical and histopathologic diagnoses
were performed and conformed to established criteria
[17,18]. All of the SSc-ILD biopsies were characterised
by a fibrotic NSIP pattern, and the IPF biopsies by a UIP
pattern, based on current consensus criteria for these
histological patterns [19]. The control tissue was histo-
logically normal. Median age (range) was 60 (52–78) in
controls, 48 (38–69) in SSc-ILD, and 61 (44–67) in IPF.
The gender distribution (M/F) was as follows: controls
6/4; SSc-ILD 2/6; IPF 2/1. Four of the SSc-ILD and two
of the IPF patients were ex-smokers. Smoking status was
not available for all control cases. In SSc-ILD patients,
median (range) percent predicted FVC was 72.5% (61–
106), median FEV1 was 79% (58–92) and median DLCO
was 50% (24–58). In IPF patients, median FVC was 70%
(64–75), median FEV1 was 66% (55–79), and median
DLCO was 50% (35–53). Patients had not been on corti-
costeroids or other immunosuppressants prior to surgical
biopsy, as the biopsy was performed at the time of diagno-
sis of the ILD pattern, prior to initiation of treatment. In-
formed written consent was given by all subjects, and
authorisation given by the Royal Brompton Hospital Eth-
ics Committee. Fibroblasts were obtained from the biop-
sies by explant culture, and cell cultures maintained, as
previously described [20,21]. Experiments were performed
on fibroblasts at passage 2–5. Only one sample (S1) was
used at passage 2. There was no difference in the median
passage number between the control (median: 4.5; range:
3–5), SSc-ILD (median: 4; range: 2–5) and IPF (median: 4;
range 3–5) groups.
Microarray gene expression and analysis
At confluence, lung fibroblasts were serum-deprived for
42 hours (media changed at 18 hours) in the presence of
0.1% bovine serum albumin (Sigma). Total RNA was
harvested (Trizol, Life Technologies), quantified, and the
integrity verified by denaturing gel electrophoresis. Samples
Table 1 qRT-PCR primers
Gene Forward primer Reverse primer
Normalisation genes
HPRT1 TGACACTGGCAAAACAATGCA GGTCCTTTTCACCAGCAAGCT
YWHAZ ACTTTTGGTACATTGTGGCTTCAA CCGCCAGGACAAACCAGTAT
Genes of interest
CXCL10 GAAAGCAGTTAGCAAGGAAAG ATCCTTGGAAGCACTGCATC
ID1 CCAGAACCGCAAGGTGAG GGTCCCTGATGTAGTCGATGA
IFITM1 TTCTTGAACTGGTGCTGTCT ATGAGGATGCCCAGAATCAG
IL11 CCTGTGGGGACATGAACTGT AGGGTCTGGGGAAACTCG
IRF1 CAGCCCAAGAAAGGTCCTC TTGAACGGTACAGACAGAGCA
NOX4 CTGCTGACGTTGCATGTTTC CGGGAGGGTGGGTATCTAA
Serpine
1
GGAAAGGCAACATGACCAG CAGGTTCTCTAGGGGCTTCC
STAT1 GGATCAGCTGCAGAACTGGT TTTCTGTTCCAATTCCTCCAA
Shown are the primers, written 5’ to 3’, used for measuring expression levels
by qRT-PCR for validation of the microarray results. All primer pairs except for
YWHAZ, IRF1, and ID1, are intron spanning.
Lindahl et al. Respiratory Research 2013, 14:80 Page 3 of 14
http://respiratory-research.com/content/14/1/80with a 28S:18S ratios of approximately 2:1 were accepted
for further analysis by the Genomics Laboratory, CSC-
MRC, Imperial College London, Hammersmith. RNA
samples were prepared for chip hybridisation following
manufacturer’s guidelines (Affymetrix). Hybridisation of
cRNA to Affymetrix human U133Av2 chips, containing
approximately 14,500 well characterised human genes,
signal amplification, and data collection were performed
using an Affymetrix fluidics station and chip reader,
according to manufacturer’s protocol. Array normalisa-
tion, using the invariant set normalisation method, and
subsequent calculation of model-based expression values,
was performed using DNA-Chip Analyzer (dChip) [22]. A
list of differentially expressed genes was generated in
dChip using fold change ≥2, difference in means ≥100,
and p<0.05. Significance analysis of microarrays (SAM) v
4.0 [23] was also used to determine significantly differen-
tially expressed genes with fold change ≥2, difference in
means ≥100, delta =1, and a false discovery rate <0.01.
Only genes identified as differentially expressed according
to both programs were considered as different between
groups. Microarray data has been deposited in the Gene
Expression Omnibus database [24], accession number
GSE40839. Although the main aim of this study was to as-
sess global gene expression profiles in SSc-ILD compared
to controls, for completeness we present the comparison
between both SSc-ILD and IPF and controls separately in
tables. dChip software was used for data visualisation and
hierarchical average linkage clustering using Pearson’s cor-
relation [22].
Functional category analysis
Functional categories enriched in the differentially
expressed genes were identified using the functional an-
notation and clustering tool of the Database for Annota-
tion, Visualisation, and Integrated Discovery (DAVID) v
6.7 [25,26]. The probability that a Gene Ontology (GO)
biological process term [27] is overrepresented was de-
termined by a modified Fisher’s exact test, comparing
the proportion of genes in the whole genome which are
part of that GO term, to the proportion of the differentially
expressed genes which are part of the same GO term, and
was expressed as an EASE score. Clusters of overrepre-
sented GO terms were then generated based on the simi-
larity of differentially expressed genes assigned to each
functional GO term. Clusters were considered significantly
overrepresented if they contained a minimum of five GO
terms with an EASE score of ≤ 0.01. A summary descrip-
tion of each cluster was generated based on the constitu-
tive GO term names of that cluster which achieved an
EASE score <0.05 following Benjamini-Hotchberg correc-
tion of multiple comparisons. Only clusters with enrich-
ment scores >3 (minus log transformed geometric mean of
the EASE scores of the constitutive terms, equivalent toaverage EASE score=0.001) were selected. The open access
database INTERFEROME [28] was used to identify differ-
entially expressed genes which have been shown experi-
mentally to be regulated by interferons.
qRT-PCR
RNA was extracted using the RNeasy® Mini kit (Qiagen)
according to manufacturer’s instructions. Samples were
quantified and quality assessed using the NanoDrop
spectrophotometry system (Thermo Scientific). Com-
plementary DNA (cDNA) was synthesised from 500 ng
RNA in a 20 μl reaction using the QuanTitect® reverse
transcription kit (Qiagen). Expression levels were mea-
sured using a Rotor Gene 6000 (Corbett) in 10 μl reac-
tions containing 2 μl cDNA (five-fold dilution), 1 ×
SensiMix™ SYBR NO-ROX (Bioline), and 0.5 μM of each
forward and reverse primer (Table 1). PCR conditions
were: 10 minutes at 95°C, followed by 40 cycles of
10 seconds at 95°C, 15 seconds at 57°C, and 5 seconds
at 72°C. All reactions were performed in duplicate and
non-template controls were included for each gene.
Standard curves were generated for each gene studied
using seven two-fold serial dilutions, high standard of
1×107 copies/μl, of primer set amplicons generated from
cDNA. Threshold cycle was manually determined at a
fixed value of 10-0.5 and the template quantity calculated
using Rotor Gene 6000 Series Software 1.7 (Corbett).
Expression levels were normalised to YWHAZ and
HPRT1 [29,30].
Western blot analysis
Following pre-incubation for 24 hours in serum-free
media (DMEM, 0.1% BSA, penicillin/streptomycin), pul-
monary fibroblasts from healthy controls, SSc-ILD, and
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ther 24 hours in fresh serum-free media. Cells were
lysed and western blot analysis was performed using the
following primary antibodies: CTGF and STAT1 (Santa
Cruz Biotechnology); αSMA (Dako); IFITM1-3, ISG15
and GAPDH (Abcam); IRF-1 (Cell Signaling Technol-
ogy); horseradish peroxidise conjugated secondary anti-
bodies (Dako and Cell Signaling Technology); and ECL
detection (Amersham).
Results
Gene expression profiles of fibrotic lung fibroblasts:
approximately two-thirds of differentially expressed
genes are down-regulated
Using an Affymetrix platform (U133Av2), we determined
basal (serum free) global gene expression levels in fibro-
blasts prepared from lung tissue of 8 patients with SSc-
ILD and 10 control lungs. As a further comparison we
also included 3 fibroblast cultures from lung tissue of
IPF patients. Unsupervised hierarchical cluster analysis
of samples and genes resulted in an overall separation of
fibrotic samples from controls (Figure 1). Two of the
SSc-ILD samples clustered among the normal controls,
demonstrating recognised fibrotic fibroblast sample
heterogeneity.
When stringent criteria were applied, as described in
the methods section, 478 and 744 probe sets (probes in
future), equivalent to 360 and 547 genes, displayed dif-
ferential expression by at least two-fold in SSc-ILD and
IPF fibroblasts, respectively, compared to control fibro-
blasts. In SSc-ILD fibroblasts, 125 probes (99 genes)
showed significantly higher, and 353 probes (261 genes)
lower expression levels compared with controls (Additional
file 1). In IPF fibroblasts, 239 and 505 probes (181 and 366
genes) had significantly higher and lower expression, re-
spectively, compared with control fibroblasts (Additional
file 2). Thus, approximately two thirds of differentially
expressed genes were expressed at lower levels in fibro-
blasts from the two disease groups compared with con-
trols. The sets of underexpressed genes in the disease
groups, compared to normal controls, also contained the
most significantly differentially expressed genes. Table 2
lists the 20 most significantly differentially expressed, and
highest ranking (fold change) genes in SSc-ILD and IPFS2 C8 C9 C7 S5 C3 C1
0
C1 C2 C5 C4
Figure 1 Unsupervised clustering of samples based on full microarray
clustering using all 22 K probes, shows clustering of samples by phenotypesamples, separately, versus controls. It should be noted
here that, while 379 out of a total of 843 probes were
differentially expressed in both SSc-ILD and IPF vs.
controls, most genes falling outside this overlap were
very nearly significant in the other disease group, i.e.
followed similar trends without meeting cut-off criteria.
When the two disease groups were compared directly,
only 8 probes (7 genes) were significantly differentially
expressed (Additional file 3). The 843 probes differen-
tially expressed in SSc-ILD and/or IPF, which also in-
clude the genes differentially expressed between these
two groups, are listed in Additional file 4. Within the
pooled fibrotic samples (IPF and SSc-ILD), no significant
difference was observed in the 843 probes according to
smoking status (SAM analysis, data not shown).
Expression levels of a subset of genes identified by the
present microarray analysis were verified by qRT-PCR in
the microarray RNA samples demonstrating good cor-
relation between these two techniques (Figure 2). Pro-
tein levels for six differentially expressed genes, fibrosis
related genes; connective tissue growth factor (CTGF),
and alpha-smooth muscle actin (αSMA), and interferon
stimulated genes (ISG); signal transducer and activator
of transcription 1 (STAT1), IFITM1-3 (all three isoforms
are detected by this antibody), ISG15 and IRF-1, were
determined by western blot analysis in independent
preparations of additional SSc-ILD, IPF, and control fi-
broblasts (Figure 3).
Functional groups over-represented among differentially
expressed genes
As predicted from the similarities between the two disease
groups with regards to differentially expressed genes, gene
ontology analysis revealed a major overlap in overrepre-
sented functional groups. Enriched functional groups
representing six broad categories (GO clusters) were iden-
tified among the genes with higher expression in disease fi-
broblasts compared with normal controls (see Table 3 for a
summary of enriched clusters of GO terms, and Additional
file 5 for full GO analysis): anatomical structure develop-
ment, regulation of cell cycle, response to stress and
wounding, regulation of apoptosis, cell migration, and
smooth muscle contraction. Among underexpressed/
downregulated genes, GO clusters included: inflammatoryC6 S4 S6 S3 S7 S8 S1 U1 U2 U3
probe set. The sample dendrogram resulting from hierarchical
: control (C, green bar), SSc-ILD (S, orange bar), IPF (U, red bar).
Table 2 Most differentially expressed genes in SSc-ILD and IPF compared to controls
Genes overexpressed in SSc-ILD vs. Control Probe set ID Control mean SSc-ILD mean Fold change p value
Inhibitor of DNA binding 1, dominant negative helix-loop-helix protein 208937_s_at 25.5 917.5 36.1 0.00078
Interleukin 11 206924_at 23.6 717.8 30.4 0.015
Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein 207826_s_at 27.7 603.2 21.8 0.00051
Tetraspanin 13 217979_at 37.9 533.9 14.1 0.0033
Elastin 212670_at 43.7 396.9 9.1 0.0021
Xylosyltransferase I 213725_x_at 29.0 255.4 8.8 0.0024
Serpin peptidase inhibitor, clade E, member 1 202628_s_at 329.8 2473.2 7.5 0.0022
Basic helix-loop-helix family, member e40 201170_s_at 44.3 256.1 5.8 0.0014
Connective tissue growth factor 209101_at 467.9 2637.1 5.6 0.00068
Solute carrier family 7, member 5 201195_s_at 56.1 294.2 5.3 0.00022
Tropomyosin 1 (alpha) 206116_s_at 317.5 1619.6 5.1 0.0032
Phosphoribosyl pyrophosphate synthetase 1 208447_s_at 59.0 283.4 4.8 0.0036
Inhibin, beta A 210511_s_at 143.3 688.1 4.8 0.0012
Growth arrest and DNA-damage-inducible, beta 207574_s_at 68.1 306.6 4.5 0.0023
Coiled-coil domain containing 99 221685_s_at 85.1 373.3 4.4 0.0018
Cadherin 2, type 1, N-cadherin (neuronal) 203440_at 105.3 433.0 4.1 0.00095
Desmoplakin 200606_at 80.5 306.1 3.8 0.0016
Insulin-like growth factor binding protein 3 212143_s_at 408.6 1489.1 3.6 0.0068
Microtubule associated monoxygenase, calponin and LIM domain
containing 2
212473_s_at 184.7 667.5 3.6 0.0039
Prostaglandin-endoperoxide synthase 1 215813_s_at 102.4 362.0 3.5 0.0083
Genes underexpressed in SSc-ILD vs. Control Probe set ID Control mean SSc-ILD mean Fold change p value
Chemokine (C-X-C motif) ligand 10 204533_at 771.2 19.2 −40.1 0.00034
Chemokine (C-X-C motif) ligand 11 210163_at 179.9 5.0 −36.0 0.0027
Flavin containing monooxygenase 2 (non-functional) 211726_s_at 530.4 15.7 −33.7 0.017
Interferon-induced protein with tetratricopeptide repeats 2 217502_at 707.1 26.1 −27.1 0.0096
Vascular cell adhesion molecule 1 203868_s_at 835.2 32.2 −26.0 0.0049
Bone marrow stromal cell antigen 2 201641_at 315.8 12.5 −25.3 0.0081
Radical S-adenosyl methionine domain containing 2 213797_at 333.8 13.3 −25.1 0.0039
Interferon-induced protein 44-like 204439_at 370.7 15.4 −24.1 0.00033
Interferon-induced protein with tetratricopeptide repeats 1 203153_at 1744.2 82.6 −21.1 0.000039
2’,5’-oligoadenylate synthetase 1, 40/46 kDa 205552_s_at 374.6 18.3 −20.5 0.0014
Complement factor B 202357_s_at 837.0 42.6 −19.6 0.0036
Interferon-induced protein with tetratricopeptide repeats 3 204747_at 985.0 61.9 −15.9 0.00031
Chromosome 10 open reading frame 10 209183_s_at 208.8 13.6 −15.3 0.0062
Myxovirus resistance 1, interferon-inducible protein p78 (mouse) 202086_at 1361.9 91.2 −14.9 0.00012
Receptor (chemosensory) transporter protein 4 219684_at 196.4 13.3 −14.8 0.000091
Chemokine (C-C motif) ligand 11 210133_at 529.8 36.2 −14.6 0.0021
Retinoic acid receptor responder (tazarotene induced) 3 204070_at 239.4 17.2 −13.9 0.00024
Alcohol dehydrogenase 1B (class I), beta polypeptide 209613_s_at 268.9 19.8 −13.6 0.011
Secreted and transmembrane 1 213716_s_at 285.0 22.0 −13.0 0.0012
Interferon, alpha-inducible protein 6 204415_at 1196.6 93.7 −12.8 0.00043
Genes overexpressed in IPF vs. Control Probe set ID Control mean IPF mean Fold change p value
Interleukin 11 206924_at 23.6 2374.9 100.6 0.0019
Inhibitor of DNA binding 1, dominant negative helix-loop-helix protein 208937_s_at 25.5 752.8 29.6 0.011
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Table 2 Most differentially expressed genes in SSc-ILD and IPF compared to controls (Continued)
Tetraspanin 13 217979_at 37.9 1039.1 27.4 0.0052
NADPH oxidase 4 219773_at 12.3 323.6 26.4 0.016
Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein 207826_s_at 27.7 603.4 21.8 0.0025
Phospholamban 204939_s_at 25.7 460.1 17.9 0.035
Elastin 212670_at 43.7 766.9 17.6 0.0026
Xylosyltransferase I 213725_x_at 29.0 443.6 15.3 0.034
Galanin prepropeptide 214240_at 18.4 254.4 13.8 0.014
Cytokine receptor-like factor 1 206315_at 23.4 319.3 13.6 0.0098
Calponin 1, basic, smooth muscle 203951_at 83.0 1048.0 12.6 0.0024
Follistatin-like 3 203592_s_at 32.5 404.8 12.4 0.0048
CTP synthase 202613_at 39.5 454.7 11.5 0.000059
Endothelial cell-specific molecule 1 208394_x_at 10.2 116.8 11.4 0.031
Cadherin 6, type 2, K-cadherin (fetal kidney) 210602_s_at 26.2 298.4 11.4 0.00092
Proenkephalin 213791_at 33.7 366.7 10.9 0.00086
Adhesion molecule with Ig-like domain 2 222108_at 54.7 490.6 9.0 0.025
NUAK family, SNF1-like kinase, 1 204589_at 56.2 489.9 8.7 0.001
Tropomyosin 1 (alpha) 206117_at 30.9 261.7 8.5 0.0069
Inhibin, beta A 210511_s_at 143.3 1198.5 8.4 0.0023
Genes underexpressed in IPF vs. Control Probe set ID Control mean IPF mean Fold change p value
Interferon-induced protein with tetratricopeptide repeats 1 203153_at 1744.2 5.4 −321.4 0.000033
Myxovirus resistance 1, interferon-inducible protein p78 (mouse) 202086_at 1361.9 8.8 −154.1 0.000096
Interferon, alpha-inducible protein 6 204415_at 1196.6 11.8 −101.2 0.00027
Chemokine (C-X-C motif) ligand 10 204533_at 771.2 9.5 −81.3 0.00031
Superoxide dismutase 2, mitochondrial 221477_s_at 2180.4 29.8 −73.2 <0.000001
Myxovirus resistance 2 (mouse) 204994_at 517.3 8.5 −60.6 0.00062
Interferon induced transmembrane protein 1 (9–27) 214022_s_at 3698.0 61.4 −60.3 <0.000001
Interferon-induced protein with tetratricopeptide repeats 3 204747_at 985.0 17.2 −57.2 0.00023
Pentraxin 3, long 206157_at 1415.2 35.2 −40.2 0.000016
Interferon-induced protein 44-like 204439_at 370.7 11.6 −31.9 0.0003
Complement component 3 217767_at 457.9 14.4 −31.8 0.000072
KIAA1199 212942_s_at 799.0 30.8 −26.0 0.00027
Interferon-induced protein 35 209417_s_at 455.6 18.1 −25.1 0.000062
Chemokine (C-X-C motif) ligand 1 204470_at 637.1 26.3 −24.2 <0.000001
Growth arrest-specific 1 204457_s_at 383.2 17.2 −22.3 0.000059
Signal transducer and activator of transcription 1, 91 kDa 209969_s_at 327.3 15.3 −21.4 0.000097
Chemokine (C-C motif) ligand 2 216598_s_at 2676.4 128.3 −20.9 0.00003
Interferon-induced protein 44 214453_s_at 335.0 17.0 −19.7 0.000027
Caspase 1 (interleukin 1, beta, convertase) 211367_s_at 180.6 10.0 −18.1 <0.000001
Tumor necrosis factor, alpha-induced protein 2 202510_s_at 404.2 22.6 −17.9 0.000003
Shown are the top 20 genes, based on fold change, over and under expressed in SSc-ILD and IPF compared to controls. Where more than one probe set
corresponding to the same gene were present in the top 20, the probe with the greatest fold change or most significant p-value, is shown.
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tion of apoptosis, regulation of cell migration, regulation of
cell proliferation, and regulation of I-κB/NF-κB cascade.
By far the most enriched functional groups, compared
with control cells, in both SSc-ILD and IPF lungfibroblasts, are genes involved in immune system pro-
cesses and in microbial/viral defence, which are strongly
suppressed in both disease groups. These genes are also
among the most significantly differentially expressed
genes in this study.
Microarray qRT-PCR
Figure 2 Quantitative RT-PCR confirmation of microarray results. Expression levels of eight genes selected from the microarray data was
measured by qRT-PCR in thirteen of the samples used in the microarray. For each sample the microarray data is plotted on the left-hand axis, and
the qRT-PCR results plotted on the right-hand axis. qRT-PCR expression levels were normalised to YWHAZ and HPRT1.
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a major group suppressed in fibrotic lung fibroblasts
To visualise the differential expression across samples
and to identify co-expressed genes, average linkage clus-
ter analysis was performed using expression data for the
843 probes sets which displayed differential expression
in at least one of the two comparisons: SSc-ILD vs. con-
trol, and IPF vs. control (Figure 4A). Within this set arealso the eight probes differentially expressed when SSc-
ILD and IPF samples were compared directly. Parts of
identified gene clusters were selected to illustrate co-
expression among upregulated (Figure 4, Panels B-F)
and downregulated (Panels H-J) genes, and also to high-
light different patterns of sample heterogeneity. Overall,
a heterogeneous expression pattern was observed in the
upregulated genes, whereas downregulated genes had
CTGF
αSMA
STAT1
GAPDH
Control SSc-ILD IPF
IFITM1-3
ISG15
IRF-1
GAPDH
Control SSc-ILD IPF
A B
Figure 3 Western blot confirmation of microarray results. Protein expression levels of six significantly differently expressed genes selected
from the microarray data were visualised by western blot in fibroblast samples independent to those used in the microarray (n=3 for each
group). A) Protein expression of fibrosis related genes, CTGF and αSMA; and key regulator of interferon response, STAT1. B) Protein expression of
interferon stimulated genes (ISG): IFITM1-3, ISG15 and IRF-1.
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majority of genes in both disease groups. Among
upregulated genes, a TGF-β response signature [31,32]
including genes encoding for fibrosis mediators and
myofibroblast markers, such as SERPINE1 (PAI1), con-
nective tissue growth factor, smoothelin, and transgelin
(SM22) is prominent (Panel B). Co-expressed with these
are strongly upregulated genes: growth arrest and DNA-
damage inducible β (GADD45), xylosyltransferase 1
(XYLT1), N-cadherin, and elastin, with potential roles in
the fibrotic disease process. Groups B, C and D all con-
tain genes involved in contraction and migration, how-
ever, the degree of heterogeneity between samples differ
between these groups: in group B, the majority of fi-
brotic samples have elevated expression of smoothelin
and transgelin compared with controls; in group C,
fewer fibrotic samples, 7 out of 11, have enhanced levels
of α2 smooth muscle actin (ACTA2) expression; and in
group D, all three IPF samples, but only 3 out of 8 SSc-
ILD samples, have elevated expression of calponin 1 and
actin gamma 2 smooth muscle (ACTG2). This may indi-
cate different degrees of contractile/migratory pheno-
types among these fibrotic cell preparations. Panel E
contains ID1 and ID3, which are in the top 20 differen-
tially regulated genes in both disease groups, and are
upregulated in most of the fibrotic samples. Group F de-
picts a cluster of co-expressed cell-cycle associated genes,
including cyclins and TOPO2, which exhibit heterogeneous
expression in both disease groups. Panel G illustrates an
area with less clustering, which however includes possible
disease specific genes, e.g. Secreted protein, acidic,
cysteine-rich (SPARC) (IPF, Table 2B) and desmoplakin
(SSc-ILD) (Additional file 4). Desmoplakin is among the
top 20 most upregulated genes in SSc-ILD with an elevated
expression in 7 out of the 8 SSc-ILD fibroblast lines, but
with low expression in the three IPF cell preparations and
in all controls. Desmoplakin is part of the desmosome
complex which forms tight cell-cell contacts [33], and itsenhanced expression in SSc-ILD fibroblasts may define a
different pathogenesis and cell origin. Panels H-J shows the
marked suppressed expression of interferon stimulated
genes (ISGs), such as antiviral genes (Group H), chemokine
(Group I) and MHC class I genes (Group J). This cluster
also includes key regulators of the interferon gene pro-
gram, STAT1, interferon regulatory factor 1 (IRF1) and
interferon regulatory factor 7 (IRF7), as well as chemokine
(C-X-C motif) ligand 10 (CXCL10/IP10), one of the most
strongly suppressed genes in the study, and the most
strongly repressed chemokine in both disease groups
(Panel H and I).
Comparing the SSc-ILD and IFP fibroblast gene
expression profiles with the interferome
Since we observe a clear fibrosis/TGF-β signature to-
gether with a strongly suppressed ISG program, and
there is a well-documented antagonistic relationship be-
tween TGF-β and interferon signalling in the fibrosis lit-
erature [34], we next interrogated the Interferome, a
database of interferon regulated genes (IRGs) reported
in the literature [28]. This database includes 1996 hu-
man IRGs, of which 1581 are induced and 415 repressed
by interferons. In our study, out of the 99 and 181
overexpressed genes in SSc-ILD and IPF fibroblasts, re-
spectively, 40 (40.4%) and 55 (30.1%) genes were in the
Interferome database. Among our underexpressed genes,
out of a total of 261 and 366 in SSc-ILD and IPF fibro-
blasts, respectively, 134 (51.3%) and 173 (74.3%) genes
were in the Interferome database. The genes overlapping
with IRGs in this database are listed in Additional file 6.
The comparison revealed that many of the TGF-β re-
sponsive genes upregulated in our microarray data set
are indeed genes repressed by IFNs.
Discussion
Previous studies have shown that fibroblasts isolated
from SSc-ILD [35] and IPF [5] lungs, while displaying
Table 3 Over-represented functional terms
GO cluster Description Enrichment
score
Genes overexpressed in SSc-ILD vs. Control
1 Anatomical structure development 5.50
2 Regulation of cell cycle 4.23
3 Response to stress and wounding 3.33
Genes underexpressed in SSc-ILD vs. Control
1 Inflammatory response 11.53
2 Regulation of cell proliferation 5.16
3 Regulation of biological process 5.12
4 Inflammatory response/chemotaxis 4.81
5 Regulation of cell migration 4.33
6 Response to external stimulus 4.19
7 Regulation of apoptosis 3.78
8 Inflammatory and immune response 3.77
9 Response to biotic stimulus/ion homeostasis 3.69
10 Regulation of I-κB kinase/NF-κB cascade 3.37
Genes overexpressed in IPF vs. Control
1 Anatomical structure development/
neurogenesis
4.94
2 Regulation of apoptosis 3.95
3 Cell migration/neurogenesis 3.81
4 Regulation of cell motion 3.45
5 Response to wounding/tissue development 3.17
6 Smooth muscle contraction/Blood
circulation
3.03
Genes underexpressed in IPF vs. Control
1 Immune response 12.65
2 Response to virus, bacteria and LPS 8.66
3 Positive regulation of biological process and
cell death
5.29
4 Negative regulation of biological process
and cell death
4.91
5 Regulation of immune system and
developmental process
4.08
6 Inflammatory response/chemotaxis 3.98
7 Regulation of cell migration and adhesion 3.87
8 Inflammatory and humoral immune
response
3.63
9 Anatomical structure development 3.39
10 Response to stimulus and I-κB kinase/NF-κB
cascade
3.19
11 Response to extracellular stimulus and
oxidative stress
3.18
Using the DAVID functional annotation tool, genes over and under expressed
in SSc-ILD and IPF compared to controls were clustered according to Gene
Ontology (GO) biological process terms. Shown are the summary descriptions
and enrichment scores of the sets of enriched GO terms within each GO
cluster with an enrichment score >3.
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migratory, resistant to apoptosis, and ECM producing,
than control lung fibroblasts [36]. A greater proportion
display elevated αSMA expression, also enhancing their
contractility. These features are all consistent with the
fibroblast accumulation and scar tissue formation observed
in fibrotic lung. The so called myofibroblast phenotype is
maintained over several passages in culture [37], suggesting
an underlying epigenetic regulation, whether established
and maintained in local cells within the chronic disease set-
ting, or supporting the phenotype of a specialised infiltrat-
ing wound healing cell type [38]. Regardless of cell origin,
this feature enables in vitro studies of mechanisms under-
lying the fibrotic fibroblast phenotype.
In this study we observed a high number of differen-
tially expressed genes between SSc-ILD and/or IPF de-
rived fibroblasts, compared with controls. There was a
large overlap between expression profiles of SSc-ILD and
IPF fibroblasts, suggesting several common pathways at
this stage of the two diseases. Indeed, a direct comparison
demonstrated only seven genes with significantly different
expression between the two disease groups. Caution
should be applied, however, when interpreting data from
this direct comparison since only three IPF samples were
included here. It is possible that more genes with differen-
tial expression between the two disease groups would be
identified with a larger numbers of IPF fibroblasts sam-
ples. Such studies would also be required to verify the
sporadic observations made in this study, such as the
elevated expression levels of desmoplakin in SSc-ILD, but
not in IPF fibroblasts. Therefore, we stress that the main
objective of the study presented here was to gain an over-
view of potential SSc-ILD target genes, and the study was
not designed to detect differences between different fi-
brotic entities.
Among significantly upregulated genes in both SSc-ILD
and IPF/UIP fibroblasts, we identify a recognised fibrosis
signature, including smooth muscle actin (ACTA2), CTGF,
and PAI1 (SERPINE1), along with genes more recently as-
sociated with lung fibrogenesis, including ID1, ID3, IL11,
and NOX4. Inhibitor of DNA binding 1 and 3 (ID1 and
ID3), are target genes of bone morphogenetic proteins, and
control cell differentiation by dominant negative inhibition
of helix-loop-helix transcription factors [39]. Chambers
et al. described upregulation of ID1 in lung fibroblasts in
response to TGF-β, and linkage to the smooth muscle
phenotypic switch [31]. Increased ID1 and ID3 gene ex-
pression was also observed in lung tissue and fibroblasts
from patients with SSc-ILD by Hsu and colleagues, [15].
The ID proteins are overexpressed in many cancers,
controlling cell growth and apoptosis, and have been sug-
gested as a therapeutic target [39,40]. In fibroproliferative
stages of fibrosis, high ID1/ID3 expression could maintain
fibroblasts in a dedifferentiated, hyperproliferative, and
AB
D
C
E
F
G
H
J
I
Figure 4 Gene expression profiles of control, SSc-ILD, and IPF pulmonary fibroblasts. A) Supervised hierarchical clustering of probes. The
gene set used comprised the 843 probes with a fold change ≥2, difference in means ≥100, and p<0.05 (dChip) and FDR<0.01 (SAM), in both the
SSc-ILD or IPF samples, compared to controls, which includes also 8 probes differentially expressed between SSc-ILD and IPF samples when
compared directly. Each column corresponds to an individual sample (C= control, S=SSc-ILD, U=IPF), and each row corresponds to an individual
probe. The coloured bars to the right of the heatmap identify the location of the insets displayed in B-J. Panels B-J were selected to highlight
sample heterogeneity and/or genes co-expressed with high scoring differentially expressed genes.
Lindahl et al. Respiratory Research 2013, 14:80 Page 10 of 14
http://respiratory-research.com/content/14/1/80apoptosis resistant state. Another significantly upregulated
gene, though somewhat variably in SSc-ILD fibroblasts, is
NOX4, encoding a member of the NADPH oxidase (NOX)
proteins which generate superoxide by electron transfer to
oxygen [41]. Through its involvement in TGF-β-induced
fibroblast differentiation into myofibroblasts, two recent
studies have suggested a role for NOX4 in IPF, where it is
found to be overexpressed [41]. Specific NOX4 inhibitors
are now being developed as possible antifibrotic agents
[42]. Another potential novel target gene, GADD45B,
highly induced and coexpressed with the fibrosis related
genes in this study, is a pro-survival factor associated
with stress-resistant tumours [43], and has been found
to be upregulated in SSc skin biopsies [44].
The most striking of our observations is the strongly
and uniformly repressed ISG profile in fibrotic fibro-
blasts. Among these are genes coding for: antiviralprotein myxovirus (influenza virus) resistance 1 (MX1),
interferon gamma inducible protein p16 (IFI16), 2’,5’-
oligoadenylate synthetase 1 (OAS1), the chemokines
chemokine (C-X-C motif ) ligand 10 (CXCL10/IP10) and
chemokine (C-C motif ) ligand 11 (CCL11), and antigen
presenting MHC I molecules. Key transcriptional regula-
tors of this program, including IRF1, IRF7, and STAT1
are also suppressed. To our knowledge, the reduction in
expression of a large set of immune response/interferon
related genes has not previously been described in either
SSc-ILD or IPF derived fibroblasts, or other fibrotic lung
diseases. Global gene expression was recently evaluated
in scleroderma whole skin biopsies and matched dermal
fibroblasts. While 26 genes were differentially expressed
in both scleroderma whole skin and fibroblasts com-
pared to controls, nine were found to be discordant [45].
Interestingly, the majority of the discordant genes were
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blasts, including the ISG genes we identify as repressed
in lung fibroblasts, such as MX1, IFI16, intercellular ad-
hesion molecule 1 (ICAM1), and OAS1. While the au-
thors argue that the discordant genes are an indication
of a scarce representativeness of skin fibroblast gene ex-
pression in vivo [45], in light of our data, it is likely that
they were in fact observing the same phenomenon
reported in the current study. As these are mainly inter-
feron regulated genes, the discordance between fibroblasts
and whole tissue gene expression could be explained by
the known increase of immune cell populations in SSc
skin, likely to be overexpressing immunoregulatory genes.
The upregulation of MX1, IRF7 and STAT1 in PBMC
from SSc patients would support this notion [46,47]. The
downregulation of the ISG program both in SSc-ILD and
in IPF fibroblasts suggests that this phenomenon relates
to a local fibroblast specific, rather than systemic, pro-
fibrotic process, perhaps underpinned by a general suscep-
tibility for tissue fibrosis, common to both diseases.
Additional support for our finding of an aberrantly
regulated ISG program in fibrotic lung fibroblasts, comes
from work on two of the signature genes from this group,
CXCL10 (IP10) and STAT1. IP10 levels were found to be
downregulated in IPF lung fibroblasts by Keane et al. [48].
More recently, Coward et al. have shown, again in IPF fi-
broblasts, that epigenetic dysregulation involving both his-
tone deacetylation and hypermethylation is responsible for
targeted repression of IP10 [49]. By contrast, Hsu et al.
did not report a significant difference in expression in iso-
lated lung fibroblasts [15], a difference which may relate
to experimental design, as discussed below. Further sup-
port of a role of suppressed ISGs in pulmonary fibrosis
comes from two animal models. Mice deficient in IP10
[50], and in STAT1 [51], displayed enhanced susceptibil-
ity to pulmonary fibrosis. Based on these studies, the
suppressed ISG program indentified in fibroblasts iso-
lated from SSc-ILD and IPF lung, as presented here,
would support enhanced lung fibrosis progression
through promoting fibroblast proliferation, migration,
and apoptosis resistance. Interestingly, IFN-γ treatment
in IPF has failed to show a benefit [52], and there was a
suggestion of worse pulmonary outcomes in a study in-
vestigating treatment of SSc patients with IFN-α com-
pared with placebo [53], with the latter providing
indirect support for IFN-related mechanisms involved
in organ-specific SSc complications. There could be
several possible explanations for these disappointing re-
sults, including unexpected adverse effects through
circulating cell populations. Activation of pathways
downstream of systemically administered interferons is
likely to have different direct and indirect effects de-
pending on the cell type and tissue location. The find-
ings shown here add important information to thiscomplexity, and need to be investigated in future de-
tailed mechanistic cell and animal studies.
The signatures observed in our study are remarkably
strong, both in terms of fold difference and statistical
significance. One possible reason for this is that lung tis-
sue samples were obtained from biopsies at the time of
diagnosis, when the disease may be at a relatively early
or active wound healing stage, and when perhaps fibro-
blast proliferation (accumulation) and elastin synthesis,
rather than contraction and collagen remodelling, dom-
inate. This is in contrast to the study by Hsu et al., in
which gene expression profiles were investigated in SSc
lung tissue and fibroblasts from transplant, and therefore
possible end-stage, material, also noted by the authors as
a potential limitation [15]. Another possibility relates to
differences in in vitro culture condition as we employed
serum free media before harvest, similarly to others, in-
cluding Coward et al. [49], as opposed to in low serum
(0.5%) as applied by e.g. Hsu et al. [15]. Serum with-
drawal, a form of cellular stress, may evoke the clear
differential expression profiles observed in our study.
Whereas in the fibrotic fibroblasts an anti-apoptotic sur-
vival gene program is maintained, which may be a result
of the suppressed ISGs, this gene program may not be
subject to repression in the normal fibroblasts.
While an accepted source of control tissue in studies
of ILD [10,12], the use of control fibroblasts from cancer
resected specimens, rather than from healthy control
subjects (not available for this study), represents a po-
tential limitation. Although obtained from areas of lung
with normal histological appearance, differential gene
expression in fibroblasts derived from lungs in which
cancer has developed cannot be excluded. However, sig-
nificant gene expression differences were observed in
lung cancer associated fibroblasts compared to matched
fibroblasts from areas of normal lung from the same
patient, suggesting that the cancer associated phenotype
of lung fibroblasts is regionally limited to the cancer
stroma [54]. A further possible source of bias in gene ex-
pression is smoking history. Smoking has been shown to
be associated with interstitial fibrotic changes [55], and
is itself likely to cause changes in the expression of
certain genes. We observed no significant differences
among differentially expressed genes according to smok-
ing status in the pooled fibrotic samples, suggesting that
the observed changes were related to the fibrotic lung
disease itself rather than to smoking. However, as sub-
group numbers were small, and it was not possible to
separately analyse the two fibrotic lung diseases, further
studies are needed to carefully assess the contribution of
smoking to gene expression changes in the context of fi-
brotic lung disease.
While the general hypothesis, that a repressed inter-
feron stimulated gene program at least in part underpins
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studies, it is interesting to note the same phenomenon
in several other clinical settings where hyperplasia and
apoptosis resistance are key features; certain viruses, in-
cluding high-risk human papillomaviruses (HPV), have
evolved a mechanism to down-regulate ISGs in host
cells as an immunoevasive strategy [56], and persistent
HPV infection may lead to cervical cancer development;
breast cancer metastasis is promoted by IRF7 silencing
[57]; fibroblasts from patients with Li-Fraumeni syn-
drome become spontaneously immortalised through the
downregulation of interferon pathway genes [58]. Con-
versely, IRF1 expression reverts the phenotype of
oncogenically transformed fibroblasts [59], and IRF-1
enhancing drugs with tumour suppressing properties
are currently being developed [60]. Many similar exam-
ples in the literature lead to questions about whether fi-
brosis is a pre-cancerous state [61]. The repressed, or
aberrantly regulated, fibroblast specific interferon re-
sponse network may therefore be a common necessary
determinant allowing lung fibrosis progression to occur.
In summary, in this study comparing gene expression
profiles of fibroblasts explanted from fibrotic lung tissue
(SSc-ILD and IPF), with control fibroblasts from areas of
normal lung, we observe: an overall elevated expression
of previously reported fibrosis associated genes, with
marked heterogeneity across samples; differentially regu-
lated myofibroblast markers which correlate with the ex-
pression heterogeneity between samples; and a strongly
suppressed interferon stimulated gene program, uni-
formly present across fibrotic samples. This suppressed
gene program displays both the greatest significance and
largest fold differences in expression in our data set. Simi-
larly to functional findings in parallel fields, particularly
cancer, this group of genes, and the suppression of their
expression, could explain essential aspects of the
profibrotic fibroblast phenotype. This hypothesis will need
to be tested by future studies, with particular focus on epi-
genetic silencing as a potential underlying mechanism.Additional files
Additional file 1: Genes differentially expressed in SSc-ILD. Word
file, .txt extension. This data set contains all of the genes up- or down-
regulated in SSc-ILD fibroblasts compared to control fibroblasts. Included
are p-values from dChip analysis and q-values from SAM analysis.
Additional file 2: Genes differentially expressed in IPF. Word file, .txt
extension. This data set contains all of the genes up- or down- regulated
in IPF fibroblasts compared to control fibroblasts. Included are p-values
from dChip analysis and q-values from SAM analysis.
Additional file 3: Genes differentially expressed between IPF and
SSc-ILD. Word file, .txt extension. This data set contains all of the genes
up- or down- regulated in IPF fibroblasts compared to SSc-ILD fibroblasts.
Included are p-values from dChip analysis and q-values from SAM
analysis.Additional file 4: Summary of differentially expressed genes in SSc-
ILD and IPF. Word file, .txt extension. This data set contains all of the
genes up- or down- regulated in fibroblasts from at least one disease
group compared to control fibroblasts. Included are p-values from dChip
analysis and q-values from SAM analysis.
Additional file 5: Functional annotation clustering analysis. Excel
file, .xlsx extension. Using the DAVID functional annotation tool, genes
over and under expressed in SSc-ILD and IPF compared to controls were
clustered according to Gene Ontology biological process terms. Shown
are the enriched terms within each annotation cluster with an EASE score
threshold of ≤ 0.01, and an initial group membership of 5.
Additional file 6: Differentially expressed genes present in
Interferome. Excel file, .xlsx extension. The data set contains all of the
genes differentially expressed genes in SSc-ILD and IPF fibroblasts
compared to control fibroblasts which have been shown experimentally
to be regulated by interferons listed in the INTERFEROME database.
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